WO2025002221 - MULTI-SPECIFIC ANTIBODIES COMPRISING ANTIGEN-BINDING DOMAINS SPECIFICALLY RECOGNIZING C5AR1 AND GM-CSFR ALPHA
National phase entry:
Publication Number
WO/2025/002221
Publication Date
02.01.2025
International Application No.
PCT/CN2024/101864
International Filing Date
27.06.2024
Title **
[English]
MULTI-SPECIFIC ANTIBODIES COMPRISING ANTIGEN-BINDING DOMAINS SPECIFICALLY RECOGNIZING C5AR1 AND GM-CSFR ALPHA
[French]
ANTICORPS MULTI-SPÉCIFIQUES COMPRENANT DES DOMAINES DE LIAISON À L'ANTIGÈNE RECONNAISSANT DE MANIÈRE SPÉCIFIQUE C5AR1 ET GM-CSFR ALPHA
Applicants **
STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.
Inventors
HE, Chong
ZHAI, Wenwu
ZHOU, Zhiwen
STRAINIC, Michael George
YUAN, Ping
YI, Zuoan
Priority Data
PCT/CN2023/102813
27.06.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3680 | |
| EPO | Filing, Examination, Granting | 27425 | |
| Japan | Filing, Examination, Granting | 2854 | |
| South Korea | Filing, Examination, Granting | 3590 | |
| USA | Filing, Examination, Granting | 10290 |
Total:
47,839
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provides multi-specific (e.g., bispecific) antibodies that specifically recognize C5aR1 and GM-CSFRα, and pharmaceutical compositions comprising multi-specific (e.g., bispecific) antibodies that specifically recognize C5aR1 and GM-CSFRα. Also provided are methods of making and using these antibodies.[French]
L'invention concerne des anticorps multispécifiques (par exemple, bispécifiques) qui reconnaissent de manière spécifique C5aR1 et GM-CSFRα, et des compositions pharmaceutiques comprenant des anticorps multispécifiques (par exemple, bispécifiques) qui reconnaissent de manière spécifique C5aR1 et GM-CSFRα. L'invention concerne également des procédés de fabrication et d'utilisation de ces anticorps.